fbpx COVID-19 (Coronavirus): ADB's Response | Asian Development Bank

COVID-19 (Coronavirus): ADB's Response

ADB is supporting its developing members in responding to the COVID-19 pandemic through finance, knowledge, and partnerships.

In the Spotlight

ARTICLE | 13 JUL 2021

Q&A: Ayako Inagaki on ADB’s COVID-19 Support to Southeast Asia

Ayako Inagaki, director of human and social development at ADB’s Southeast Asia Regional Department, helps oversee ADB’s COVID-19 portfolio for Southeast Asia—$5.8 billion and counting.

NEWS RELEASE | 1 JUL 2021

ADB Establishes High-Level Advisory Group for COVID-19 Vaccines

ADB has joined with leading public health experts, vaccine regulators, and policy makers to form an advisory group to provide its developing member countries with expert technical and scientific advice on the quality, safety, and effectiveness of COVID-19 pandemic vaccines.

News Release | 08 Jul 2021

$150 Million Loan to Help Sri Lanka Purchase COVID-19 Vaccines

The Asian Development Bank has approved a loan of $150 million for Sri Lanka to purchase vaccines against the coronavirus disease (COVID-19) and improve vaccination information, delivery, and monitoring systems.

News Release

$9 Billion ADB Facility to Help Developing Member Countries Access and Distribute COVID-19 Vaccines

ADB has launched a $9 billion vaccine initiative—the Asia Pacific Vaccine Access Facility (APVAX)—offering rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

ADB’s COVID-19 response consists of a $20 billion package announced in April 2020 and the $9 billion Asia Pacific Vaccine Access Facility (APVAX) announced in December 2020.

ADB’s initial $20 billion COVID-19 response package supports its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (non-sovereign).

ADB's $9 billion APVAX vaccine initiative offers rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*Projects may be listed in more than one country or subregion. The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.

News and Multimedia   Subscribe to our newsletter

Publications and Documents


Milestones

Made with Flourish